BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2009 Financial Results on Novemb... ( LYNBROOK N.Y. Oct. 30 /- BioSpecifics...)

HOME >> BIOLOGY >> TECHNOLOGY

BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2009 Financial Results on November 5, 2009

Date:10/30/2009

LYNBROOK, N.Y., Oct. 30 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, announced today that the Company will host a conference call and live audio webcast at 4:30 p.m. ET on Thursday, November 5, 2009 to discuss its third quarter 2009 financial results and corporate highlights.

To participate in the call, please dial 800-860-2442 (domestic) or 412-858-4600 (international). The live webcast can be accessed under "Calendar of Events" in the Investor Relations section of the Company's website at www.biospecifics.com, or you may use the link: http://www.videonewswire.com/event.asp?id=63660.

A replay of the call will be available one hour after the conference ends on November 5, 2009 until 9:00am ET on November 12, 2009. To access the replay, please dial 877-344-7529 (domestic) or 412-317-0088 (international) and reference the access code 435394. The archived webcast will be available for 90 days in the Investor Relations section of the BioSpecifics' website at http://www.biospecifics.com.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for three clinical indications: Dupuytren's disease; Peyronie's disease; and frozen shoulder (adhesive capsulitis). Its strategic partner Auxilium Pharmaceuticals, Inc. has announced the acceptance of the Biologic License Application (BLA) and Priority Review by the U.S. Food and Drug Administration for injectable collagenase XIAFLEX(TM) in the treatment of Dupuytren's disease. Pfizer, Inc. is responsib
'/>"/>

SOURCE BioSpecifics Technologies Corp.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Post Your Comments:

(Date:12/16/2009)... Soy Peptone. HSP A has been found to be effectinve ... ... December 16, 2009 -- Nu-Tek BioSciences, LLC. ( www.nu-tekproducts.com ) is ... HSP-A, previously manufactured by Nutricepts, Inc. (Burnsville, Mn), is a ... rates and yields. HSP-A has been found to be especially ...

(Date:12/15/2009)... Joint BioEnergy Institute (JBEI), one of three Department of ... trusted time-stamping service to protect its valuable intellectual property. ... ... VA (PRWEB) December 15, 2009 -- Surety, LLC ... solutions , today announced that the Joint BioEnergy Institute ...

(Date:12/15/2009)... -- Reportlinker.com announces that a new market ... ,, The Future of Orphan ... Pipeline Analysis and Reimbursement ,, ... Summary ,, The author has ... Orphan Diseases Therapeutics - Market Forecasts to ...

(Date:12/15/2009)... NeedleProbes™ for Atomic Force Microscopy (AFM) have been developed ... studies at the liquid/air interface. The NeedleProbes’ cylindrical geometry ... evaporation rate and viscosity - all in a single force ... ... 15, 2009 -- New, constant diameter NeedleProbes are ...

[0] Nu-Tek BioSciences, LLC. Launches Animal-Free, Non-GM Soy Peptone [0] Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property [0] Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement [0] New Constant Diameter NeedleProbes™ with Unique Ability to Measure Liquid Surface Properties by AFM

... is licensed for the entire immunization series to ... against diphtheria, tetanus, and pertussis -, SWIFTWATER, Pa. ... division of the sanofi-aventis Group,announced today that the U.S. ... Tetanus Toxoids and Acellular,Pertussis Vaccine Adsorbed) to be administered ...

... derma fillers are,driving significant growth in the prescription ... products and technology developments. The market,was valued at ... achieve a CAGR of 7%,through 2011, lead by ... segments, according to Kalorama,Information,s new report Prescription Dermatological ...

... March 13 EntreMed, Inc.,(Nasdaq: ENMD ), ... of cancer and inflammatory diseases, today,announced its 2008 ... objectives, as well as plans for current and,future ... President and CEO, James S. Burns, during the ...

Other Biology Technology:U.S. FDA Licenses DAPTACEL(R) Vaccine for the Fifth Consecutive Dose in the Pediatric DTaP Immunization Series 2 U.S. FDA Licenses DAPTACEL(R) Vaccine for the Fifth Consecutive Dose in the Pediatric DTaP Immunization Series 3 U.S. FDA Licenses DAPTACEL(R) Vaccine for the Fifth Consecutive Dose in the Pediatric DTaP Immunization Series 4 Biologics, Derma Fillers are Key to Dermatological Drug Market Growth 2 EntreMed Announces 2008 Corporate and Clinical Program Priorities 2 EntreMed Announces 2008 Corporate and Clinical Program Priorities 3 EntreMed Announces 2008 Corporate and Clinical Program Priorities 4 EntreMed Announces 2008 Corporate and Clinical Program Priorities 5 EntreMed Announces 2008 Corporate and Clinical Program Priorities 6

U.S. FDA Licenses DAPTACEL(R) Vaccine for the Fifth Consecutive Dose in the Pediatric DTaP Immunization Series Biologics, Derma Fillers are Key to Dermatological Drug Market Growth EntreMed Announces 2008 Corporate and Clinical Program Priorities

(Date:12/16/2009)... molecules form an intricate network of interactions. Today,s ... individual molecular reactions outside the cells. Since molecular ... the laboratory, scientists suspect that the kinetics of ... external probes. We expected the cellular reaction speed ... Braun. "However, our novel optical approach showed that ...

(Date:12/16/2009)... Signal Hill, CA Tom Bowman, an expert ... of Bowman Global Change, has developed a series of ... Panel on Climate Change (IPCC) report for public audiences. ... scientific information they need to make informed decisions about ... new format as a means to clearly and accurately ...

(Date:12/16/2009)... CITY, Calif., Dec. 2 DigitalPersona, ... authentication solutions, today announced an agreement with ... its DigitalPersona biometric fingerprint technology on IBM ... 4500HD offering allows point-of-sale applications to more ... specific transactions can be linked to the ...

Breaking Biology News(10 mins):Looking for the heartbeat of cellular networks 2 Bowman creates graphic translation of climate change data 2 DigitalPersona Fingerprint Sensor Technology Ships on IBM SurePOS 500 Retail Systems 2 Elekta CMS Software Receives FDA 510 28k 29 Clearance for Monaco VMAT Treatment Planning Solution 52651 1 Elekta CMS Software Receives FDA 510 28k 29 Clearance for Monaco VMAT Treatment Planning Solution 52651 2 NeurogesX Announces Preliminary Results of FDA Requested Qutenza 28TM 29 Study 4775 1 NeurogesX Announces Preliminary Results of FDA Requested Qutenza 28TM 29 Study 4775 2 NeurogesX Announces Preliminary Results of FDA Requested Qutenza 28TM 29 Study 4775 3 NeurogesX Announces Preliminary Results of FDA Requested Qutenza 28TM 29 Study 4775 4 Alcohol and Trauma 3A Blood Test Gets to the Truth 52648 1 Alcohol and Trauma 3A Blood Test Gets to the Truth 52648 2

[0] Looking for the heartbeat of cellular networks [0] Bowman creates graphic translation of climate change data [0] DigitalPersona Fingerprint Sensor Technology Ships on IBM SurePOS 500 Retail Systems

... traditional emphasis on dense, fast-growing, conifer-dominated forests in the ... of animal species that depend on shrubs, herbs and ... and the U.S. Geological Survey suggests. , At least ... one way or another, the food or habitat provided ...

... Bluefin Are Skinny , DURHAM, N.H. The quality ... Maine has declined significantly since the early 1990s, researchers ... analyzing detailed logbooks from a commercial tuna grader at ... in Fishery Bulletin, indicate potential changes in food sources, ...

... in children 8 years of age and older in the ... report from an international team of researchers. , Nearly 2 ... a significant proportion of those experience moderate to severe symptoms, ... the August issue of the journal Pediatrics. , This study ...

Other Biology News:Emphasis on conifer forests places multiple species at risk 2 Emphasis on conifer forests places multiple species at risk 3 Condition of bluefin tuna in gulf of maine is declining 2 Condition of bluefin tuna in gulf of maine is declining 3 Restless legs syndrome affects nearly 2 percent of US/UK children 2 Restless legs syndrome affects nearly 2 percent of US/UK children 3

Emphasis on conifer forests places multiple species at risk Condition of bluefin tuna in gulf of maine is declining Restless legs syndrome affects nearly 2 percent of US/UK children

ICAD / DFF45 (NT) Affinity Purified Polyclonal Antibody...

Anti-Human IFN-Gamma Receptor Chain 2 (beta chain) [CD119], Rabbit serum, NON-neutralizing polyclonal antibody...

Anti-BAR Immunogen: Peptide of aa 3-21 from human Bar Available Date: 38226...

... the HECT protein, E6-AP and ... suggests that this E2 is ... of non-""N-end rule"" protein substrates ... proteins as well as the ...

Biology Products:

Rabbit Anti-ICAD / DFF45 (NT) Polyclonal Antibody, Unconjugated from ProSci, Inc Rabbit Anti-Human IFN-Gamma Receptor Chain 2 (beta chain) [CD119] NON-neutralizing Polyclonal Antibody, Unconjugated from Cell Sciences Rabbit Anti-Human BAR Antibody, Unconjugated from CHEMICON Anti-UbcH7 Antibody, Unconjugated from CHEMICON

BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2009 Financial Results on Novemb...( LYNBROOK N.Y. Oct. 30 /- BioSpecifics...)